| چکیده انگلیسی مقاله |
The myelodysplastic syndrome (MDS) is a heterogeneous group of clonal disorders of hematopoietic progenitor cells related to ineffective hematopoiesis and an increased risk of transformation to acute myelogenous leukemia. MDS is divided into categories, namely lineage dysplasia (MDS-SLD), MDS with ring sideroblasts (MDS-RS), MDS with multilineage dysplasia (MDS-MLD), MDS with excess blasts (MDS-EB). The International Prognostic Classification System (IPSS) ranks the patients as very low, low, intermediate, high, and very high based on disease evolution and survival rates. Evidence points to toll-like receptor (TLR) abnormal signaling as an underlying mechanism of this disease, providing a link between MDS and immune dysfunction. Microbial signals, such as lipopolysaccharides from gram-negative bacteria, can activate or suppress TLRs. Therefore, we hypothesized that MDS patients present gut microbiota alterations associated with disease subtypes and prognosis. To test this hypothesis, we sequenced the 16S rRNA gene from fecal samples of 30 MDS patients and 16 healthy elderly controls. We observed a negative correlation between Prevotella spp. and Akkermansia spp. in MDS patients compared with the control group. High-risk patients presented a significant increase in the genus Prevotella spp. compared to the other risk categories. There was a significant reduction in the abundance of the genus Akkermansia spp. in high-risk patients compared with low- and intermediate-risk. There was a significant decrease in the genus Ruminococcus spp. in MDS-EB patients compared with controls. Our findings show a new association between gut dysbiosis and higher-risk MDS, with a predominance of gram-negative bacteria. |
| نویسندگان مقاله |
| Giovanna Riello
1) Department of Clinical and Toxicological Analysis, School of Pharmacy, Federal University of Ceara, Fortaleza, CE, Brazil 2) Drug Research and Development Center. Faculty of Medicine, Federal University of Ceara, Fortaleza, CE, Brazil
| Priscila Silva
University Hospital Walter Cantidio, Federal University of Ceara, Brazil Brazilian Company of Hospital Services (EBSERH), Fortaleza, Ceará, Brazil
| Francisca Andrea Oliveira
Drug Research and Development Center, Faculty of Medicine, Federal University of Ceara, Fortaleza, CE, Brazil
| Roberta de Oliveira
Cancer Cytogenomic Laboratory, Drug Research and Development Center, Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceara, Fortaleza, Brazil
| Francisco Eliclecio da Silva
Laboratory of Neuropsychopharmacology, Drug Research and Development Center, Faculty of Medicine, Federal University of Ceara, Fortaleza, CE, Brazil
| Ivo França
Cancer Cytogenomic Laboratory, Drug Research and Development Center, Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceara, Fortaleza, Brazil
| Fábio Miyajima
Oswaldo Cruz Foundation (Fiocruz), Branch Ceara, Eusebio, Brazil
| Vânia Melo
Laboratory of Microbial Ecology and Biotechnology, Department of Biology, Federal University of Ceará, Fortaleza, Brazil
| Ronald Pinheiro
Cancer Cytogenomic Laboratory, Drug Research and Development Center, Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceara, Fortaleza, Brazil
| Danielle Macedo
Laboratory of Neuropsychopharmacology, Drug Research and Development Center, Faculty of Medicine, Federal University of Ceara, Fortaleza, CE, Brazil
|